Microbiological Surveillance of Peritoneal Dialysis Associated Peritonitis: Antimicrobial Susceptibility Profiles of a Referral Center in GERMANY over 32 Years

Daniel Kitterer¹, Joerg Latus¹, Christoph Pöhlmann², M. Dominik Alscher¹, Martin Kimmel¹*

¹ Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany, ² Department of Diagnostic and Laboratory Medicine, Robert-Bosch-Hospital, Stuttgart, Germany

* martin.kimmel@rbk.de

Abstract

Objectives
Peritonitis is one of the most important causes of treatment failure in peritoneal dialysis (PD) patients. This study describes changes in characteristics of causative organisms in PD-related peritonitis and antimicrobial susceptibility.

Methods
In this single center study we analyzed retrospective 487 susceptibility profiles of the peritoneal fluid cultures of 351 adult patients with peritonitis from 1979 to 2014 (divided into three time periods, P1-P3).

Results
Staphylococcus aureus decreased from P1 compared to P2 and P3 (P<0.05 and P<0.01, respectively). Methicillin-resistant S. aureus (MRSA) occurred only in P3. Methicillin-resistant Staphylococcus epidermidis (MRSE) increased in P3 over P1 and P2 (P<0.0001, respectively). In P2 and P3, vancomycin resistant enterococci were detected. The percentage of gram-negative organisms remained unchanged. Third generation cephalosporin resistant gram-negative rods (3GCR-GN) were found exclusively in P3. Cefazolin-susceptible gram-positive organisms decreased over the three decades (93% in P1, 75% in P2 and 58% in P3, P<0.01, P<0.05 and P<0.0001, respectively). Vancomycin susceptibility decreased and gentamicin susceptibility in gram-negatives was 94% in P1, 82% in P2 and 90% in P3. Ceftazidim susceptibility was 84% in P2 and 93% in P3.

Conclusions
Peritonitis caused by MSSA decreased, but peritonitis caused by MRSE increased. MRSA peritonitis is still rare. Peritonitis caused by 3GCR-GN is increasing. An initial antibiotic treatment protocol should be adopted for PD patients to provide continuous surveillance.
Introduction

Since continuous ambulatory peritoneal dialysis (CAPD) was invented in the early 80’s of the last century, peritoneal dialysis (PD) has become a standard of care in end-stage renal disease (ESRD) patients [1]. Approximately 200,000 patients worldwide are treated with PD, which represents 11% of the global dialysis population [2]. However, peritonitis remains one of the principal complications, despite all reasonable preventative strategies [3]. The incidence of PD-associated peritonitis varies from 0.06–1.66 episodes/patient-year in different centers and different countries [4]. Peritonitis can lead to treatment failure and termination of the procedure in 20% of patients and has a mortality of 2–6% [5, 6]. Empirical antibiotic strategies must cover both gram-positive and gram-negative organisms. The Society for Peritoneal Dialysis (ISPD) has recommended center-specific empirical therapy. The antibiotic regimen should be selected according to local antimicrobial susceptibility profiles [7]. Intraperitoneal administration of antibiotics was superior to intravenous administration for treating PD-associated peritonitis [8, 9]. The ISPD guidelines emphasize the need to monitor resistance among various gram-negative bacteria [4, 7]. It is therefore essential to develop and implement an antibiotic stewardship program to improve empirical therapy and to monitor the resistance rates in PD-associated peritonitis.

Here we report the antimicrobial susceptibility profiles and distribution of causative organisms in our referral center in Germany over more than three decades.

Materials and Methods

Ethical Considerations

The Ethical Commission of the Medical University of Tuebingen approved this study (Ethical Approval/Registration Number: 103/2015R). The analysis was performed retrospective without written or verbal informed consent to participate in this study. Due to the long study period and the retrospective anonymous analysis of the data, nevertheless the lack of informed consent has been approved by the local ethics committee.

Study Population

We analyzed all peritonitis episodes from January 1979 to December 2014 at the Robert-Bosch-Hospital, Stuttgart, Germany. Peritonitis was defined as the presence of abdominal pain and/or cloudy effluent with a cell count greater than 100/μL, with at least 50% polymorphonuclear cells as stated in the current guidelines of the International Society for Peritoneal Dialysis (ISPD) [7]. A systematic review of all peritoneal fluid cultures (PFC) was performed in our laboratory. During this period, 487 PFC from 351 adult patients were documented, of which 61 PFC were culture negative (12.5%) and were excluded from the study (P1 = 12 culture negative episodes, ratio culture positive/culture negative 10:1; P2 = 15 culture negative episodes, ratio culture positive/culture negative 8:1; P3 = 34 culture negative episodes, ratio culture positive/culture negative 7:1). Episodes with peritoneal eosinophilia and negative PFC were also excluded from the study. Nasal mupirocin application in all S. aureus carriers began in 1994. Since the early 90s, PD nurses provide intensive training in every „new“PD patient in our center. In patients with S. aureus exit-site colonization topical antibiotic at the catheter exit in agreement with the current ISPD guidelines were used [7]. Prior to 1994, no antibiotic therapy was used as a prophylaxis for peritonitis.

Microbiological specimen collection, antimicrobial susceptibility testing and data analyses. The abdomen was drained and effluent was collected from the patient’s outlet bag. Dialysate effluent was collected under sterile conditions and 10ml effluent was incubated per blood
culture bottle (BCB) for at least two BCBs (aerobic/anaerobic) as recommended by the ISPD Guidelines [7, 10, 11]. BCBs were used from bioMérieux (Germany) and BD (Germany) and were routinely incubated for seven days. Positive BCBs were subcultured on both aerobic and anaerobic standard media. Etiologic identification of grown organisms was performed employing specific metabolic reactions in conventional manual (Api test systems, bioMérieux, Germany) or automated test systems (VITEK 2, bioMérieux, Germany). Since 2011, identification of bacteria was primarily done using the MALDI Biotyper System (Bruker Corporation Billerica, USA). The VITEK 2 system, which was implemented in 2003, was also used for susceptibility testing of bacteria. Before 2003, agar diffusion was the dominant technique for sensitivity testing. However, until now it is still used in the minority of cases due to its simplicity. If the agar diffusion technique was used, no minimum inhibitory concentration (MIC) was available. 

In Vitro susceptibility was defined according to the limit specifications (breakpoints) of the Clinical and Laboratory Standards Institute (CLSI) [12]. Strains presenting intermediate values were considered to be resistant. For comparison, the PFC samples were divided into three periods (2 from 1979–1991, period 2 1993–2003, period 3 2004–2014). The susceptibility profiles of each organism were determined from the data.

**Empiric therapy during the study period.** From 1979 to 2011 the empiric therapy at our center was cefazolin intraperitoneal (i.p.) and gentamycin i.p. in PD patients with peritonitis. After interim analysis of the shown microbiological data, empiric therapy was changed to vancomycin i.p. and gentamycin i.p. in 2014.

### Statistical Analyses

Comparisons between the three groups were performed with the Fisher’s exact test (two-tailed). Analysis was performed using the statistical software package Prism (GraphPad San Diego, California, USA). $P < 0.05$ was considered significant.

### Results

#### Distribution of Organisms

We analyzed 487 susceptibility profiles of patients with PD-associated peritonitis since the PD was begun in January 1979 at the Robert-Bosch-Hospital, Germany. In P1, 66 PD patients were treated (in total 120 peritonitis episodes) in our center. In P2, the number of PD patients remained stable (69 patients with 125 peritonitis episodes). The number of PD patients increased in P3 (130 PD patients with 241 peritonitis episodes). Over the whole study period (P1–P3) there was a slight increase of gram-negative bacteria and a slight decrease of gram-positive bacteria. The ratio of gram-negative to gram-positive bacteria increased from 0.4 in P1 to 0.5 in P3 ($P > 0.05$, Fig 1).

**Distribution of Gram-positive organisms.** Gram-positive organisms caused 70% of the peritonitis episodes. In period 1, we found a significant surplus of *Staphylococcus aureus* compared to period 2 and period 3 as shown in Table 1 ($P < 0.05$ and $P < 0.01$, respectively). In period 1 and period 2 only methicillin-sensitive *S. aureus* (MSSA) strains could be detected. In the last period, two strains of methicillin-resistant *S. aureus* were found (1% of all episodes). Simultaneously, the proportion of methicillin-resistant *Staphylococcus epidermidis* (MRSE) increased in period 3 compared to period 1 and 2 ($P < 0.0001$, respectively). The percentage of *Enterococcus* spp. increased from 4% to 7% over the three decades, but the difference was not statistically significant (period 1 compared to period 3). In period 1, no vancomycin resistant enterococcus (VRE) was detected. However in period 2 and period 3, VRE appeared (13% and 19% of all *Enterococcus* spp., respectively), but the difference was not statistically significant.
The percentage of gram-negative organisms remained unchanged over the three decades (Table 1, Fig 1).

**Distribution of SPICE (Serratia, Pseudomonas/Providencia, indole-positive Proteus/ Acinetobacter/Morganella, Citrobacter, Enterobacter or Hafnia) and third generation cephalosporin resistant organisms.**  
Period 1: Two *Acinetobacter* spp. (2%), one *Serratia* spp., one *Citrobacter* spp. (0.8%, respectively) and three *Enterobacter* spp. (2.5%) occurred.

Period 2: Four *Acinetobacter* spp. (3%), one *Proteus* spp. (0.8%), one *Serratia* spp. (0.8%, four *Citrobacter* spp. (3.2%), one *Enterobacter* spp. (0.8%) and one *Morganella* spp. (0.8%) occurred.

Period 3: Three *Acinetobacter* spp. (1%), four *Serratia* spp. (1.7%), two *Citrobacter* spp. (0.8%) and three *Enterobacter* spp. (1.2%) occurred. Furthermore, two *E. coli* (6.5%), two *Klebsiella* spp. (22.2%), one *Acinetobacter baumannii* (33.3%) and one *Aeromonas hydrophila* (6.7% of other gram-negative organisms) were classified as being resistant against third generation cephalosporin (3GCR-GN), mainly due to ESBL and/or derepressed AmpC phenotypes. All strains were susceptible to imipenem. Proportions of the various microorganisms are shown in Table 1.

**In Vitro Susceptibility Rates**

The *in vitro* susceptibilities observed in the three periods are shown in Tables 2 and 3, respectively. For MSSA, the proportion of bacteria susceptible to gentamicin was statistically different
between period 1 and period 2 (Table 2). Susceptibility to gentamicin was 70% in P1 and increased to 100% in P2. For doxycycline, the proportion of susceptible strains increased from 70% in period 1 to 100% in period 3. The difference was statistically significant (P < 0.05). In Streptococcus spp., susceptibility to Levofloxacin increased from 33% in period 1 to 82% in P3 (P < 0.001). In E. coli, susceptibility to trimethoprim/sulfamethoxazole (TXM-SMX) decreased from 83% in period 1 to 63% period 2. In period 3, susceptibility to TXM-SMX increased to 84% (P < 0.0001).

**In Vitro Susceptibility Rates to empiric initial intraperitoneal therapies.**

**Gram-positive organisms.** In period 1, the susceptibility rate to cefazolin was 93%. In period 2, the susceptibility rate decreased to 75% and in P3 to 58% (P < 0.01, P < 0.05 and
In period 1, 79% of all gram-positive strains were sensitive to gentamicin. In period 2, the susceptibility decreased to 58% and in period 3 the susceptibility increased to 71%. The difference between period 1 and period 3 was not significant ($P = 0.2$). Sensitivity to vancomycin was almost equal over the three periods (98–100%) (Tables 4–6, Fig 2).

**Discussion**

In this study we focused on the microbiological pattern with corresponding *in vitro* antibiotic susceptibility rates for PD-associated peritonitis over three decades in our center in Germany. To our knowledge, this analysis of the distribution of causative organisms in PD-related peritonitis and antimicrobial susceptibility profiles covers the longest time period studied. Over the study period we found a slight, non-significant, increase of gram-negative bacteria and a slight...
A decrease of gram-positive bacteria reflected by an increase of the ratio from gram-negative to gram-positive bacteria (0.4 in P1 to 0.5 in P3).

In our study population, S. aureus decreased from period 1 to period 3. Scottish data reported a decrease in S. aureus-associated peritonitis over a four-year period [13], whereas a study from Korea reported no decrease over a decade [14]. It was postulated that the introduction of the double-bag (twin-bag) system in the 1980s, technical evolutions, S. aureus screening and treatment with mupirocin was responsible for this development [15–17]. Proportions of peritonitis-associated CNS episodes declined from 29% in period 1 to 12% in period 3 in our patients. This agrees well with previous studies [18]. On the other hand, the proportions of MRSE episodes increased over the three decades to 19% as described for other populations [14, 19]. Interestingly, MRSA associated peritonitis remains a rare event with only two episodes in period 3. In our study, susceptibility to cefazolin in gram-positive organisms decreased over the three decades (period 1 compared to period 2), but the difference was not statistically significant. On the other hand the percentage of Enterococcus spp. varied between 4% and 7%.

This indicates a favor for treatment with vancomycin as a first line antibiotic regimen in our in

| Table 3. Gram-negative organisms causing Peritoneal Dialysis-\-Related Peritonitis and their In Vitro Susceptibility Rates over 32 years. |
|---------------------------------------------------------------|
| **Pseudomonas spp. n (% susceptible)** | **Klebsiella spp. n (% susceptible)** | **Escherichia coli n (% susceptible)** | **Other Gram-negative organisms##. n (% susceptible)** |
| P1 | P2 | P3 | P | P1 | P2 | P3 | P | P1 | P2 | P3 | P |
| Ampicillin | 7 (57) | 1 (100) | — | 3 (0) | 2 (0) | 9 (0) | — | 12 (67) | 11 (45) | 28 (46) | NS | 7 (14) | 12 (8) | 11 (27) | NS |
| Amp/Sulb | NT | NT | 1 (100) | — | NT | 2 (50) | 9 (78) | — | NT | 9 (67) | 30 (80) | — | NT | 11 (9) | 11 (57) | NS |
| Cefotaxim | 7 (57) | 1 (0) | NT | — | 3 (100) | 1 (100) | 9 (78) | NS | 12 (100) | 2 (100) | 27 (89) | NS | 5 (100) | NT | 11 (91) | NS |
| Ceftazidime | 2 (100) | 8 (75) | NT | — | 10 (100) | NT | 9 (78) | NS | NT | 11 (100) | 31 (94) | NS | NT | 12 (100) | 14 (93)b | NS |
| Cefepime | NT | 2 (50) | NT | — | 10 (100) | NT | 8 (75) | — | NT | 2 (100) | 31 (97) | — | NT | NT | 14 (93)b | — |
| Gentamicin | 7 (86) | 8 (100) | NT | — | 10 (90) | NT | 9 (89) | NS | 12 (100) | 11 (82) | 31 (97) | NS | 7 (100) | 12 (83) | 14 (71)b | NS |
| Imipenem | 4 (100) | 8 (100) | NT | — | 10 (100) | NT | 9 (89) | NS | 11 (100) | 11 (100) | 31 (100) | NS | 1 (100) | 12 (92) | 14 (100)b | NA |
| Ofloxacin | NT | NT | NT | — | NT | 1 (100) | NT | — | NT | 2 (100) | NT | — | NT | 7 (100) | — |
| Ciprofloxacin | NT | 8 (100) | NT | — | 10 (80) | NT | 9 (89) | — | NT | 1 (100) | 4 (75) | 31 (87) | — | NT | NT | 14 (57) | — |
| Levofoxacin | NT | 8 (100) | NT | — | 10 (80) | NT | 9 (89) | — | NT | 8 (63) | 31 (84) | NS | NT | 5 (100) | 14 (57)b | NS |
| TMX-SMX | 7 (57) | 1 (0) | NT | — | 3 (33) | NT | 9 (100) | NS | 12 (83) | 11 (64) | 31 (84) | <0.0001# | 6 (83) | 12 (67) | 13 (77) | NS |
| **Episodes** | 7 | 8 | 10 | 3 | 2 | 9 | 12 | 11 | 31 | 7 | 13 | 15 |  |  |  |
| Episode | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  |  |  |

P1 = period 1 (1979–1992); P2 = period 2 (1993–2003); P3 = period 3 (2004–2014); NT, not tested; number of antibiograms; percentage of full susceptibility; Amp/Sulb, ampicillin/sulbactam; TMX-SMX, trimethoprim/sulfamethoxazole; NA, not available;
##including Enterobacteriaceae (except Eschericha coli and Klebsiella supp.), except Acinetobacter spp.;
###Pseudomonas oryzihabitans;
####Neisseria spp. was not tested;
#comparison between period 2 and period 3; NS, not significant;

doi:10.1371/journal.pone.0135969.t003
hospital patient cohort. Though in period 2 and period 3 VRE appeared, this is an important point that must be considered if initial treatment is not effective. Gram-negative organisms are often resistant to antibiotics because of either an plasmid encoded beta lactamase (e.g., extended beta lactamase (ESBL) producers) or chromosomally mediated beta-lactamases (e.g. derepressed AmpC beta-lactamase); these organisms are summarized by the acronym SPICE (Serratia, Pseudomonas/Providencia, indole-positive Proteus/ Acinetobacter/Morganella, Citrobacter, Enterobacter or Hafnia) [20, 21]. In total, we found no significant increase in gram-negative peritonitis over the three decades. However, third generation cephalosporin resistant gram-negative rods (3GCR-GN) increased in the last period from 2004–2014. ESBL-producing E. coli peritonitis is associated with a worse outcome [22] and must therefore be considered in daily clinical practice. Both first line regimens for gram-negative organisms have had similar susceptibility profiles for gram-negative organisms. Susceptibility to ceftazidim varied between 100% and 84%. Sensitivity to gentamicin varied between 82% and 94%. This indicates the need for alternative antibiotic regimens if first line therapy fails or in vitro testing indicates a resistance to one of the antibiotics. The current rise in 3GCR-GN indicated the need of a carbapenem antibiotic regimen in the treatment of PD-associated peritonitis. A small prospective open-label study showed that monotherapy with imipenem/cilastatin has similar efficacy compared to cefazolin plus ceftazidine or netilmicin in the treatment of PD-associated peritonitis [23]. To limit the risk of under- and overdosing, routine measurement of blood concentrations should be performed [24]. However, randomized controlled trials for the use of carbapenems in PD peritonitis are lacking. The ISPD outlines the importance of a surveillance program in each PD center to adapt the empiric therapy to the local resistance spectrum [7]. As a consequence of our local antimicrobial surveillance we changed the empiric therapy in PD patients

Table 4. In Vitro Susceptibility Rates of different pathogens to empiric initial intraperitoneal therapies in period 1 (1979–1992).

| 1979–1992          | Cefazolin n (% susceptible) | Ceftazidim n (% susceptible) | Gentamicin n (% susceptible) | Vancomycin n (% susceptible) |
|--------------------|----------------------------|-------------------------------|-------------------------------|-------------------------------|
| **Gram-positive organisms** |                            |                               |                               |                               |
| Staphylococcus aureus | 23 (100)                  | 4 (100)                       | 23 (70)                       | 17 (100)                      |
| MSSA                | 23 (100)                  | 4 (100)                       | 23 (70)                       | 17 (100)                      |
| MRSA               | NA                        | NA                            | NA                            | NA                            |
| CNS                | 41 (95)                   | NT                            | 41 (68)                       | 16 (100)                      |
| MRSE               | NT                        | NT                            | 6 (67)                        | 6 (100)                       |
| Enterococcus spp.  | NT                        | NT                            | 5 (80)                        | NT                            |
| Streptococcus spp. | 13 (85)                   | 3 (67)                        | 13 (54)                       | 6 (100)                       |
| Other gram positive rods | 2 (100)             | NT                            | 2 (100)                       | 2 (100)                       |
| Others             | 3 (67)                    | NT                            | 3 (100)                       | 1 (100)                       |
| **Gram-negative organisms** |                        |                               |                               |                               |
| Pseudomonas spp.   | NT                        | 3 (100)                       | 7 (86)                        | NT                            |
| Stenotrophomonas spp. | NT                      | N                             | NA                           | NT                            |
| Escherichia coli   | NT                        | NT                            | 12 (100)                      | NT                            |
| Klebsiella spp.    | NT                        | NT                            | 3 (100)                       | NT                            |
| Acinetobacter spp. | NT                        | NT                            | 3 (100)                       | NT                            |
| Others             | NT                        | NT                            | 7 (86)                        | NT                            |

MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; CNS, coagulase-negative staphylococci; NA, not available, NT, not tested; variables are expressed in number of antibiograms (percentage in parentheses regarding Susceptibility Rate); doi:10.1371/journal.pone.0135969.t004
with peritonitis from “cefazolin i.p. and gentamycin i.p.” to “vancomycin i.p. and gentamycin i.p. in 2014.

Hence, our data illustrate the appropriateness of ISPD guidelines recommending center-specific selection of empirical therapy. Furthermore, it must be noted that *in vitro* sensitivity testing is often not sufficient in clinical practice.

Our study has several limitations. First we presented data from a single center in southern Germany with an in-hospital patient cohort. The total number of episodes was different in the three decades due to an increase number in patients treated by our center. Second, different microbiological techniques for etiologic identification of organisms and susceptibility testing were used during the three decades. Third all *in vitro* susceptibility was defined according to CLSI but limit specifications of the CLSI varied over time. Fourthly the available data does not allow a differentiation between ESBL and AmpC beta-lactamases ESBL producing strains could only suspect by resistance to third generation cephalosporins.

Fifth, due to the long study period and the conception of our center as a referral center, the clinical data regarding peritonitis rate and PD details are incomplete. Very recently, Esch et al. reported the incidence of peritonitis, causative pathogens and clinical outcomes from 1979 to July 2010 from a PD center in the Netherlands including PD details, but without susceptibility rates [25].

In conclusion, we found a decrease in S. *aureus* and CNS associated peritonitis over the three decades, whereas the proportion of MRSE increased during the period. MRSA peritonitis is a rare event and peritonitis caused by 3GCR-GN increased. Susceptibility to cefazolin in

| 1993–2003 | Cefazolin n (% susceptible) | Ceftazidim n (% susceptible) | Gentamicin n (% susceptible) | Vancomycin n (% susceptible) |
|------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Gram-positive organisms | 81 (75) | 4 (25) | 73 (58) | 81 (99)* |
| *Staphylococcus aureus* | 11 (91) | NT | 11 (91) | 11 (100) |
| MSSA | 11 (91) | NT | 11 (91) | 11 (100) |
| MRSA | NA | NA | NA | NA |
| CNS | 35 (63) | NT | 35 (60) | 35 (100) |
| MRSE | NT | NT | 9 (67) | 9 (100) |
| *Enterococcus* spp. | NT | NT | 8 (63) | 8 (88)* |
| *Streptococcus* spp. | 22 (91) | NT | 15 (20) | 23 (100) |
| Other gram positive rods | 3 (67) | 2 (0) | 3 (67) | 3 (100) |
| Others | 1 (0) | NT | 1 (0) | 1 (100) |
| Gram-negative organisms | NT | 38 (84) | 38 (82) | NT |
| *Pseudomonas* spp. | NT | 8 (75) | 8 (100) | NT |
| *Stenotrophomonas* spp. | NT | 1 (0) | 1 (0) | NT |
| *Escherichia coli* | NT | 11 (100) | 11 (82) | NT |
| *Klebsiella* spp. | NT | 2 (100) | 2 (50) | NT |
| *Acinetobacter* spp. | NT | 4 (25) | 3 (75) | NT |
| Others | NT | 12 (100)* | 12 (83)* | NT |

MSSA, methicillin-sensitive *S. aureus*; MRSA, methicillin-resistant *S. aureus*; CNS, coagulase-negative staphylococci; MRSE, methicillin-resistant *Staphylococcus* epidermidis; NA, not available; NT, not tested;

*one vancomycin resistant enterococcus (VRE);

*bacteroides spp.; variables are expressed in number of antibiograms (percentage in parentheses regarding Susceptibility Rate);*

doi:10.1371/journal.pone.0135969.t005
Table 6. *In Vitro* Susceptibility Rates of different pathogens to empiric initial intraperitoneal therapies in period 3 (2004–2014).

|                                   | 2004–2014 Cefazolin n (% susceptible) | Ceftazidim n (% susceptible) | Gentamicin n (% susceptible) | Vancomycin n (% susceptible) |
|-----------------------------------|--------------------------------------|-----------------------------|-----------------------------|-------------------------------|
| **Gram-positive organisms**       |                                       |                             |                             |                               |
| Staphylococcus aureus             | 17 (88)                              | NT                          | 17 (88)                     | 17 (100)                      |
| MSSA                              | 15 (100)                             | NT                          | 15 (100)                    |                               |
| MRSA                              | 2 (0)                                | NT                          | 2 (0)                       |                               |
| CNS                               | 73 (38)                              | NT                          | 73 (70)                     | 70 (100)                      |
| MRSE                              | NT                                   | NT                          | NT                          |                               |
| Enterococcus spp.                 | NT                                   | NT                          | NT                          | 16 (81)                       |
| Streptococcus spp.                | 19 (95)                              | NT                          | 10 (40)                     | 39 (100)                      |
| Other gram positive rods          | 2 (0)                                | 2 (100)                     | 10 (70)                     | 10 (100)                      |
| Others                            | 1 (100)                              | 3 (100)                     | 3 (100)                     | 4 (100)                       |
| **Gram-negative organisms**       |                                       |                             |                             |                               |
| Pseudomonas spp.                  | NT                                   | 10 (100)                    | 10 (90)                     | NT                            |
| Stenotrophomonas spp.             | NT                                   | 1 (100)                     | 1 (100)                     | NT                            |
| Escherichia coli                  | NT                                   | 31 (94)                     | 31 (94)                     | NT                            |
| Klebsiella spp.                   | NT                                   | 9 (78)                      | 9 (89)                      | NT                            |
| Acinetobacter spp.                | NT                                   | 3 (33)                      | 3 (100)                     | NT                            |
| Others                            | NT                                   | 14 (93)                     | 14 (71)                     | NT                            |

MSSA, methicillin-sensitive *S. aureus*; MRSA, methicillin-resistant *S. aureus*; CNS, coagulase-negative staphylococi; MRSE, methicillin-resistant Staphylococcus epidermidis; NA, not available; NT, not tested; 

* Gemella morbillorum, Micrococcus luteus

*Vancomycin resistant enterococcius (VRE);

*third generation cephalosporin resistant gram-negative rods (3GCR-GN); variables are expressed in number of antibiograms (percentage in parentheses regarding Susceptibility Rate);

doi:10.1371/journal.pone.0135969.t006

Fig 2. *In vitro* susceptibility to empirical intraperitoneal treatment. A. Gram-positive organisms; B. Gram-negative organisms; P1, period 1 (1979–1992), n = 120 episodes; P2, period 2 (1993–2003), n = 125 episodes; P3, period 3 (2004–2014), n = 242 episodes; all variables are expressed as percentage.

doi:10.1371/journal.pone.0135969.g002
gram-positive organisms decreased over the three decades but vancomycin was effective in all episodes except in VRE. Susceptibility to gentamicin and ceftazidim was comparable. Our data suggests that it is necessary to implement local antibiotic stewardship strategies in PD programs.

**Author Contributions**

Conceived and designed the experiments: MK MDA. Performed the experiments: DK JL MDA CP MK. Analyzed the data: DK JL MDA CP. Contributed reagents/materials/analysis tools: DK JL MDA CP MK. Wrote the paper: DK JL MK MDA CP.

**References**

1. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005; 20(12):2587–93. PMID: 16204281
2. Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012; 23(3):533–44. doi: 10.1681/ASN.2011060607 PMID: 22302194
3. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst Rev. 2004;(4):CD004679. PMID: 15495124
4. Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int. 2011; 31(6):614–30. doi: 10.3747/pdi.2011.00057 PMID: 21880990
5. Boudville N, Kemp A, Clayton P, Lim W, Badve SV, Hawley CM, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol. 2012; 23(8):1398–405. doi: 10.1681/ASN.2011121135 PMID: 22626818
6. Troidle L, Finkelstein F. Treatment and outcome of CPD-associated peritonitis. Ann Clin Microbiol Antimicrob. 2006; 5:6. PMID: 16600033
7. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010; 30(4):393–423. doi: 10.3747/pdi.2010.00049 PMID: 20628102
8. Ballinger AE, Palmer SC, Wiggins KJ, Craig JC, Johnson DW, Cross NB, et al. Treatment for peritoneal dialysis-associated peritonitis. Cochrane Database Syst Rev. 2014; 4:CD005284. doi: 10.1002/14651858.CD005284.pub3 PMID: 24771351
9. Weber J, Staerz E, Mettang T, Machleidt C, Kuhlmann U. Treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) with intraperitoneal cefazolin and gentamicin. Perit Dial Int. 1989; 9(3):191–5. PMID: 2488364
10. Keane WF, Everett ED, Golper TA, Gokal R, Halstenson C, Kawaguchi Y, et al. Peritoneal dialysis-associated peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis. Perit Dial Int. 1993; 13(1):14–28. PMID: 8443273
11. Boeschoten EW, Ter Wee PM, Divino J. Peritoneal dialysis-related infections recommendations 2005—an important tool for quality improvement. Nephrol Dial Transplant. 2006; 21 Suppl 2:i31–3. PMID: 16825257
12. Institute CaLS. Performance standards for antimicrobial susceptibility testing: Clinical and Laboratory Performance Standards Institute; 2014.
13. Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999–2002). Nephrol Dial Transplant. 2004; 19(10):2584–91. PMID: 15304559
14. Kim DK, Yoo TH, Ryu DR, Xu ZG, Kim HJ, Choi KH, et al. Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade. Perit Dial Int. 2004; 24(5):424–32. PMID: 15490981
15. Bazzato G, Coli U, Landini S, Fracasso A, Morachiello P, Righetto F, et al. The double bag system for CAPD reduces the peritonitis rate. Trans Am Soc Artif Intern Organs. 1984; 30:690–2. PMID: 6533959
16. Daly C, Campbell M, Cody J, Grant A, Donaldson C, Vale L, et al. Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage renal disease. Cochrane Database Syst Rev. 2001;(2):CD003078. PMID: 11406668
17. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group. J Am Soc Nephrol. 1996; 7(11):2403–8. PMID: 8959632
18. Szeto CC, Chow KM, Kwan BC, Law MC, Chung KY, Yu S, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. Clin J Am Soc Nephrol. 2007; 2 (2):245–51. PMID: 17699420

19. Holley JL, Bernardini J, Johnston JR, Piraino B. Methicillin-resistant staphylococcal infections in an outpatient peritoneal dialysis program. Am J Kidney Dis. 1990; 16(2):142–6. PMID: 2382651

20. Friedman O, Jassal SV, Bargman JM. Acinetobacter peritoneal dialysis peritonitis: description and relation to the SPICE family of organisms. Perit Dial Int. 2008; 28(2):195–7. PMID: 18332457

21. Chao CT, Lee SY, Yang WS, Chen HW, Fang CC, Yen CJ, et al. Acinetobacter peritoneal dialysis peritonitis: a changing landscape over time. PLoS One. 2014; 9(10):e110315. doi: 10.1371/journal.pone.0110315 PMID: 25314341

22. Yip T, Tse KC, Lam MF, Tang S, Li FK, Choy BY, et al. Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients. Perit Dial Int. 2006; 26(2):191–7. PMID: 16623424

23. Leung CB, Szeto CC, Chow KM, Kwan BC, Wang AY, Lui SF, et al. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis—a randomized controlled trial. Perit Dial Int. 2004; 24(5):440–6. PMID: 15490983

24. Vlaar PJ, van Hulst M, Benne CA, Janssen WM. Intraperitoneal compared with intravenous meropenem for peritoneal dialysis-related peritonitis. Perit Dial Int. 2013; 33(6):708–9. doi: 10.3747/pdi.2012.00155 PMID: 24335130

25. van Esch S, Krediet RT, Struijk DG. 32 years’ experience of peritoneal dialysis-related peritonitis in a university hospital. Perit Dial Int. 2014; 34(2):162–70. doi: 10.3747/pdi.2013.00275 PMID: 24584620